X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6099) 6099
Publication (488) 488
Book Review (197) 197
Book Chapter (38) 38
Magazine Article (27) 27
Conference Proceeding (12) 12
Book / eBook (6) 6
Dissertation (3) 3
Newsletter (1) 1
Presentation (1) 1
Reference (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4651) 4651
index medicus (2478) 2478
male (2325) 2325
animals (2116) 2116
female (2099) 2099
cyclooxygenase inhibitors - therapeutic use (1780) 1780
anti-inflammatory agents, non-steroidal - adverse effects (1581) 1581
anti-inflammatory agents, non-steroidal - therapeutic use (1480) 1480
nonsteroidal antiinflammatory drugs (1448) 1448
pharmacology & pharmacy (1398) 1398
celecoxib (1352) 1352
cyclooxygenase inhibitors - adverse effects (1306) 1306
middle aged (1210) 1210
cox-2 inhibitors (1125) 1125
aged (1042) 1042
cyclooxygenase 2 inhibitors - therapeutic use (1020) 1020
adult (1015) 1015
cyclooxygenase 2 (892) 892
cyclooxygenase 2 - metabolism (841) 841
rats (801) 801
cyclooxygenase 2 inhibitors - adverse effects (800) 800
rheumatoid-arthritis (771) 771
membrane proteins (759) 759
cyclooxygenase 2 inhibitors (743) 743
mice (742) 742
cyclooxygenase inhibitors - pharmacology (738) 738
cyclooxygenase-2 (729) 729
inflammation (712) 712
cyclooxygenase (677) 677
sulfonamides - therapeutic use (676) 676
risk factors (670) 670
treatment outcome (642) 642
nonsteroidal anti-inflammatory drugs (619) 619
rofecoxib (600) 600
double-blind method (557) 557
aspirin (546) 546
osteoarthritis (546) 546
sulfonamides - adverse effects (534) 534
dose-response relationship, drug (533) 533
expression (515) 515
anti-inflammatory agents, non-steroidal - pharmacology (514) 514
cox-2 (498) 498
risk (491) 491
analysis (486) 486
isoenzymes - antagonists & inhibitors (461) 461
medicine, general & internal (453) 453
gastrointestinal toxicity (452) 452
double-blind (445) 445
cyclooxygenase 2 inhibitors - pharmacology (443) 443
oncology (414) 414
care and treatment (410) 410
cancer (406) 406
nsaids (403) 403
lactones - therapeutic use (401) 401
cyclooxygenase inhibitors - administration & dosage (393) 393
lactones - adverse effects (389) 389
pain (380) 380
osteoarthritis - drug therapy (379) 379
prostaglandin-endoperoxide synthases - metabolism (378) 378
medicine & public health (373) 373
prevention (372) 372
research (361) 361
pyrazoles - therapeutic use (356) 356
drug therapy (354) 354
aspirin - adverse effects (343) 343
cyclooxygenase 2 inhibitors - administration & dosage (343) 343
inhibition (342) 342
aged, 80 and over (338) 338
prostaglandin-endoperoxide synthases (338) 338
anti-inflammatory agents, non-steroidal - administration & dosage (337) 337
rheumatology (336) 336
pain - drug therapy (329) 329
aspirin - therapeutic use (326) 326
gastroenterology & hepatology (323) 323
prostaglandins (323) 323
drug therapy, combination (322) 322
indomethacin (321) 321
gastrointestinal diseases - chemically induced (308) 308
sulfones - therapeutic use (307) 307
pyrazoles (306) 306
cyclooxygenase 2 - genetics (304) 304
sulfones - adverse effects (301) 301
surgery (299) 299
rats, wistar (298) 298
adolescent (296) 296
disease models, animal (296) 296
sulfones (294) 294
cardiovascular diseases - chemically induced (292) 292
randomized controlled trials as topic (290) 290
drugs (289) 289
biochemistry & molecular biology (286) 286
time factors (284) 284
arthritis, rheumatoid - drug therapy (283) 283
health aspects (283) 283
sulfonamides - pharmacology (278) 278
clinical trials as topic (274) 274
ibuprofen (274) 274
naproxen (274) 274
pyrazoles - adverse effects (274) 274
immunology (273) 273
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5838) 5838
German (125) 125
French (59) 59
Japanese (34) 34
Spanish (29) 29
Russian (17) 17
Dutch (15) 15
Chinese (12) 12
Italian (10) 10
Swedish (10) 10
Finnish (9) 9
Polish (9) 9
Hungarian (6) 6
Croatian (4) 4
Czech (4) 4
Hebrew (4) 4
Bulgarian (3) 3
Norwegian (3) 3
Korean (2) 2
Ukrainian (2) 2
Bosnian (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Internal Medicine, ISSN 0003-4819, 10/2003, Volume 139, Issue 7, pp. 539 - I29
Gastrointestinal (GI) toxicity mediated by dual cyclooxygenase (COX)-1 and COX-2 inhibition of nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious... 
Naproxen - adverse effects | Prospective Studies | Double-Blind Method | Humans | Middle Aged | Male | Lactones - adverse effects | Osteoarthritis - drug therapy | Naproxen - therapeutic use | Lactones - therapeutic use | Cardiovascular Diseases - complications | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Hypertension - complications | Female | Aspirin - therapeutic use | Drug Therapy, Combination | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Gastrointestinal Diseases - chemically induced | Sulfones | Osteoarthritis - complications | IBUPROFEN | MEDICINE, GENERAL & INTERNAL | CARDIOVASCULAR THROMBOTIC EVENTS | CYCLOOXYGENASE-2 | EFFICACY | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NSAIDS | TOXICITY | COX-2 INHIBITOR ROFECOXIB | HEALTH | ASPIRIN | Evaluation | COX-2 inhibitors | Rofecoxib | Drug therapy | Osteoarthritis | Naproxen | Comparative Study | Cardiovascular Diseases/complications | Cyclooxygenase Inhibitors/adverse effects/therapeutic use | Aspirin/therapeutic use | Hypertension/complications | Osteoarthritis/complications/drug therapy | Naproxen/adverse effects/therapeutic use | Lactones/adverse effects/therapeutic use | Drug Therapy; Combination | Research Support; Non-U.S. Gov't | Gastrointestinal Diseases/chemically induced | Anti-Inflammatory Agents; Non-Steroidal/adverse effects/therapeutic use
Journal Article
世界胃肠病学杂志:英文版, ISSN 1007-9327, 2008, Volume 14, Issue 28, pp. 4535 - 4539
Journal Article
Evidence‐Based Child Health: A Cochrane Review Journal, ISSN 1557-6272, 09/2006, Volume 1, Issue 3, pp. 812 - 845
Journal Article
Circulation, ISSN 0009-7322, 06/2006, Volume 113, Issue 25, pp. 2906 - 2913
Background-The selective cyclooxygenase-2 (COX-2) inhibitors and other nonselective nonsteroidal antiinflammatory drugs ( NSAIDs) have been associated with... 
Drugs | Myocardial infarction | Cyclooxygenase-2 inhibitors | Mortality | Nonsteroidal antiinflammatory drugs | RHEUMATOID-ARTHRITIS | POPULATION | CARDIAC & CARDIOVASCULAR SYSTEMS | drugs | CARDIOVASCULAR EVENTS | myocardial infarction | CONVERTING ENZYME-INHIBITORS | RANDOMIZED CONTROLLED-TRIAL | CELECOXIB | BLOOD-PRESSURE | nonsteroidal antiinflammatory drugs | mortality | CYCLO-OXYGENASE-2 INHIBITORS | ROFECOXIB | PERIPHERAL VASCULAR DISEASE | BETA-BLOCKERS | HEMATOLOGY | cyclooxygenase-2 inhibitors | Ibuprofen - therapeutic use | Multivariate Analysis | Recurrence | Sulfones - therapeutic use | Confidence Intervals | Myocardial Infarction - mortality | Pyrazoles - therapeutic use | Patient Readmission | Humans | Middle Aged | Sulfones - adverse effects | Male | Dose-Response Relationship, Drug | Cyclooxygenase 2 Inhibitors - adverse effects | Cyclooxygenase 2 Inhibitors - therapeutic use | Aged, 80 and over | Female | Registries | Retrospective Studies | Odds Ratio | Pyrazoles - adverse effects | Diclofenac - therapeutic use | Diclofenac - adverse effects | Risk Factors | Proportional Hazards Models | Celecoxib | Lactones - adverse effects | Lactones - therapeutic use | Cross-Over Studies | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Myocardial Infarction - drug therapy | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Denmark | Sulfonamides - adverse effects | Aged | Ibuprofen - adverse effects
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9573, pp. 1621 - 1626
Summary Background Guidelines on pain management recommend that patients at risk of ulcers receive either a cyclo-oxygenase (COX 2) inhibitor or a... 
Internal Medicine | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NSAID | CYCLOOXYGENASE-2 INHIBITORS | ARTHRITIS PATIENTS | NAPROXEN | COMPLICATIONS | HELICOBACTER-PYLORI | PEPTIC-ULCER | CELECOXIB | Pyrazoles - therapeutic use | Humans | Esomeprazole - adverse effects | Male | Secondary Prevention | Osteoarthritis - drug therapy | Esomeprazole - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Female | Drug Therapy, Combination | Pyrazoles - adverse effects | Anti-Ulcer Agents - therapeutic use | Double-Blind Method | Proton Pump Inhibitors | Risk Factors | Anti-Ulcer Agents - adverse effects | Peptic Ulcer Hemorrhage - chemically induced | Treatment Outcome | Celecoxib | Peptic Ulcer Hemorrhage - therapy | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Sulfonamides - adverse effects | Aged | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Prevention | Complications and side effects | COX-2 inhibitors | Relapse | Gastrointestinal bleeding | Peptic ulcer | Proton pump inhibitors | Dosage and administration | Drug therapy | Diseases | Drugs | Medical research | Physical examinations | Hospitals | Analgesics | Ulcers | Terminal illnesses | Clinical trials | Pharmaceuticals
Journal Article
The Lancet, ISSN 0140-6736, 2004, Volume 364, Issue 9435, pp. 675 - 684
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10087, pp. 2375 - 2382
Summary Background Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require... 
Internal Medicine | RHEUMATOID-ARTHRITIS | CYCLO-OXYGENASE-2 | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PHARMACOLOGY | DICLOFENAC | PREVENTION | RISK | OSTEOARTHRITIS | Celecoxib - administration & dosage | Recurrence | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Secondary Prevention - methods | Aspirin - administration & dosage | Cyclooxygenase 2 Inhibitors - adverse effects | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Naproxen - administration & dosage | Cyclooxygenase 2 Inhibitors - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Aged, 80 and over | Aspirin - therapeutic use | Drug Therapy, Combination | Celecoxib - adverse effects | Naproxen - adverse effects | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Cyclooxygenase 2 Inhibitors - administration & dosage | Peptic Ulcer Hemorrhage - chemically induced | Celecoxib - therapeutic use | Proton Pump Inhibitors - therapeutic use | Naproxen - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Arthritis - drug therapy | Aged | Care and treatment | Aspirin | Anti-inflammatory drugs | Gastrointestinal diseases | Naproxen | Clinical trials | Arthritis | Complications and side effects | Medical research | Gastrointestinal bleeding | Medicine, Experimental | Drugs | Funding | Risk | Population studies | Hemorrhage | Bleeding | Incidence | Prostaglandin endoperoxide synthase | Motivation | Safety | Nonsteroidal anti-inflammatory drugs | Antiinflammatory agents | Digestive system | Risk reduction | Inflammation | Celecoxib | Patients | Diseases | Omeprazole | Random numbers | Inhibitors | Ulcers | Healing | Fatalities | Cyclooxygenase-2 | Cardiovascular diseases | Health risk assessment
Journal Article